Search results
Thinking Of Buying Pfizer For Its 5.8% Dividend Yield? Consider This Alternative Option Instead
Benzinga via Yahoo Finance· 7 days agoPfizer Inc. (NYSE:PFE) has long been a favorite among income investors, thanks to its generous...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 1 day agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 15 hours agoPharma giant Pfizer Inc. (NYSE: PFE) announced on Wednesday after markets closed that its gene...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 11 hours agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 14 hours agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...
Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne muscular...
FierceBiotech· 1 day agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 1 day agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Pfizer’s gene therapy for a muscle-wasting disorder misses main goal of late-stage study
WSAU Wausau· 1 day ago(Reuters) - Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting...
Pfizer Inc. (NYSE:PFE) Shares Sold by Cresset Asset Management LLC
ETF DAILY NEWS· 2 days agoCresset Asset Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 13.5% in the fourth quarter, according to the company in its most recent disclosure ...